SPC
DXCM icon

Slate Path Capital’s DexCom DXCM Stock Holding History

Slate Path Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-632,000
Closed -$78.4M – 67
2023
Q4 		$78.4M Buy
+632,000
New +$64.6M 1.74% 25
2018
Q2 		– Sell
-372,000
Closed -$6.9M – 20
2018
Q1 		$6.9M Buy
372,000
+92,000
+33% +$1.36M 0.44% 24
2017
Q4 		$4.02M Sell
280,000
-92,000
-25% -$1.2M 0.4% 19
2017
Q3 		$4.55M Buy
+372,000
New +$6.58M 0.24% 20
2017
Q2 		– Sell
-4,478,000
Closed -$94.9M – 17
2017
Q1 		$94.9M Buy
+4,478,000
New +$87.4M 4.64% 12

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Slate Path Capital's DXCM Position: Q1 2024 in Review

Slate Path Capital sold out of DexCom (DXCM) in Q1 2024, closing a stake of 632,000 shares — an estimated $78.4M sold.

Slate Path Capital first reported a position in DXCM in Q1 2017 and held it in 5 quarters. The position peaked at $94.9M in Q1 2017. 1,033 funds tracked by Wall St. Rank hold DXCM as of Q1 2024.

  • Slate Path Capital reported no remaining DexCom position as of Q1 2024 after selling out during the quarter.
  • Slate Path Capital sold 632,000 DexCom shares in Q1 2024, an estimated $78.4M.
  • Slate Path Capital first reported a position in DexCom in Q1 2017 and held it in 5 quarters.
  • Slate Path Capital's DexCom position peaked at $94.9M in Q1 2017.
  • 1,033 funds tracked by Wall St. Rank held DexCom as of Q1 2024.

Based on Slate Path Capital's 13F filing for Q1 2024, filed 15 May 2024.